retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial 40mg Lilly's triple agonist delivers up
Description
J Neurosci Res (2020) 98(11):235769
These innovative biologics have revolutionized diabetes management by offering superior glycemic control alongside significant weight loss benefits, positioning them as preferred treatment options over traditional therapies
The regions large and diverse population presents a significant opportunity for market expansion, especially as awareness of innovative weight loss therapies continues to rise
Not optional
Han SM, Namkoong C, Jang PG, Park IS, Hong SW, Katakami H, et al
